Short-term treatment with silymarin improved 6-OHDA-induced catalepsy and motor imbalance in hemi-parkisonian rats

Advanced Pharmaceutical Bulletin

Volumn 5, Issue 4, 2015, Pages 463-469

  Haddadi, Rasool ^a   Brooshghalan, Shahla Eyvari ^b   Farajniya, Safar ^b   Nayebi, Alireza Mohajjel ^b,c   Sharifi, Hamdolah ^d  

^a HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d URMIA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

6 OHDA; Catalepsy; Motor disturbance; Rat; Silymarin

Indexed keywords

OXIDOPAMINE; SILYMARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALEPSY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; MALE; MORNING DOSAGE; MOTOR COORDINATION; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NONHUMAN; PARKINSON DISEASE; RAT; SHORT COURSE THERAPY; SUBSTANTIA NIGRA PARS COMPACTA;

EID: 84949685207     PISSN: 22285881     EISSN: 22517308     Source Type: Journal    
DOI: 10.15171/apb.2015.063     Document Type: Article

References (38)

1. Warner TT, Schapira AH. Genetic and environmental factors in the cause of parkinson's disease. Ann Neurol 2003;53 Suppl 3:S16-23; discussion S-5. doi: 10.1002/ana.10487
2. Jenner P, Olanow CW. The pathogenesis of cell death in parkinson's disease. Neurology 2006;66(10 Suppl 4):S24-36.
3. Dauer W, Przedborski S. Parkinson's disease: Mechanisms and models. Neuron 2003;39(6):889-909.
4. Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordower JH, Rodriguez M, et al. Missing pieces in the parkinson's disease puzzle. Nat Med 2010;16(6):653-61. doi: 10.1038/nm.2165
5. Hirsch EC, Hunot S. Neuroinflammation in parkinson's disease: A target for neuroprotection? Lancet Neurol 2009;8(4):382-97. doi: 10.1016/S1474-4422(09)70062-6
6. Lee JK, Tran T, Tansey MG. Neuroinflammation in parkinson's disease. J Neuroimmune Pharmacol 2009;4(4):419-29. doi: 10.1007/s11481-009-9176-0
7. Mandegary A, Saeedi A, Eftekhari A, Montazeri V, Sharif E. Hepatoprotective effect of silyamarin in individuals chronically exposed to hydrogen sulfide; modulating influence of tnf-alpha cytokine genetic polymorphism. Daru 2013;21(1):28. doi: 10.1186/2008-2231-21-28
8. Manna SK, Mukhopadhyay A, Van NT, Aggarwal BB. Silymarin suppresses tnf-induced activation of nf-kappa b, c-jun n-terminal kinase, and apoptosis. J Immunol 1999;163(12):6800-9.
9. Gupta OP, Sing S, Bani S, Sharma N, Malhotra S, Gupta BD, et al. Anti-inflammatory and anti-arthritic activities of silymarin acting through inhibition of 5-lipoxygenase. Phytomedicine 2000;7(1):21-4. doi: 10.1016/S0944-7113(00)80017-3
10. Esmaily H, Vaziri-Bami A, Miroliaee AE, Baeeri M, Abdollahi M. The correlation between nf-kappab inhibition and disease activity by coadministration of silibinin and ursodeoxycholic acid in experimental colitis. Fundam Clin Pharmacol 2011;25(6):723-33. doi: 10.1111/j.1472-8206.2010.00893.x
11. Haddadi R, Mohajjel Nayebi A, Brooshghalan SE. Pre-treatment with silymarin reduces brain myeloperoxidase activity and inflammatory cytokines in 6-ohda hemi-parkinsonian rats. Neurosci Lett 2013;555:106-11. doi: 10.1016/j.neulet.2013.09.022
12. Galhardi F, Mesquita K, Monserrat JM, Barros DM. Effect of silymarin on biochemical parameters of oxidative stress in aged and young rat brain. Food Chem Toxicol 2009;47(10):2655-60. doi: 10.1016/j.fct.2009.07.030
13. Muzes G, Deak G, Lang I, Nekam K, Gergely P, Feher J. Effect of the bioflavonoid silymarin on the in vitro activity and expression of superoxide dismutase (sod) enzyme. Acta Physiol Hung 1991;78(1):3-9.
14. Nencini C, Giorgi G, Micheli L. Protective effect of silymarin on oxidative stress in rat brain. Phytomedicine 2007;14(2-3):129-35. doi: 10.1016/j.phymed.2006.02.005
15. Raza SS, Khan MM, Ashafaq M, Ahmad A, Khuwaja G, Khan A, et al. Silymarin protects neurons from oxidative stress associated damages in focal cerebral ischemia: A behavioral, biochemical and immunohistological study in wistar rats. J Neurol Sci 2011;309(1-2):45-54. doi: 10.1016/j.jns.2011.07.035
16. Hou YC, Liou KT, Chern CM, Wang YH, Liao JF, Chang S, et al. Preventive effect of silymarin in cerebral ischemia-reperfusion-induced brain injury in rats possibly through impairing nf-kappab and stat-1 activation. Phytomedicine 2010;17(12):963-73. doi: 10.1016/j.phymed.2010.03.012
17. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. San Diego: Elsevier Academic Press; 2007.
18. Mohajjel Nayebi A, Nazemiyeh H, Omidbakhsh R, Çobanoglu S. Analgesic effect of the methanol extract of Erica arborea (L.) in mice using formalin test. Daru 2008;16(4): 229-32.
19. Haddadi R, Nayebi AM, Farajniya S, Brooshghalan SE, Sharifi H. Silymarin improved 6-ohda-induced motor impairment in hemi-parkisonian rats: Behavioral and molecular study. Daru 2014;22:38. doi: 10.1186/2008-2231-22-38
20. Carvalho MM, Campos FL, Coimbra B, Pego JM, Rodrigues C, Lima R, et al. Behavioral characterization of the 6-hydroxidopamine model of parkinson's disease and pharmacological rescuing of non-motor deficits. Mol Neurodegener 2013;8:14. doi: 10.1186/1750-1326-8-14
21. Schwarting RK, Huston JP. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol 1996;50(2-3):275-331.
22. Deumens R, Blokland A, Prickaerts J. Modeling parkinson's disease in rats: An evaluation of 6-ohda lesions of the nigrostriatal pathway. Exp Neurol 2002;175(2):303-17. doi: 10.1006/exnr.2002.7891
23. Sharifi H, Mohajjel Nayebia A, Farajnia S. The effect of chronic administration of buspirone on 6-hydroxydopamine-induced catalepsy in rats. Adv Pharm Bull 2012;2(1):127-31. doi: 10.5681/apb.2012.019
24. Sharifi H, Mohajjel Nayebia A, Farajnia S. Dose-dependent effect of flouxetine on 6-ohda-induced catalepsy in male rats: A possible involvement of 5-ht1a receptors. Adv Pharm Bull 2013;3(1):203-6. doi: 10.5681/apb.2013.033
25. Sharifi H, Nayebi AM, Farajnia S, Haddadi R. Effect of chronic administration of buspirone and fluoxetine on inflammatory cytokines in 6-hydroxydopamine-lesioned rats. Drug Res (Stuttg) 2014. doi: 10.1055/s-0034-1374615
26. Sharifi H, Mohajjel Nayebi A, Farajnia S. 8-oh-dpat (5-ht1a agonist) attenuates 6-hydroxy-dopamine-induced catalepsy and modulates inflammatory cytokines in rats. Iran J Basic Med Sci 2013;16(12):1270-5.
27. Mahmoudi J, Nayebi AM, Samini M, Reyhani-Rad S, Babapour V. Buspirone improves the anti-cataleptic effect of levodopa in 6-hydroxydopamine-lesioned rats. Pharmacol Rep 2011;63(4):908-14.
28. Mahmoudi J, Mohajjel Nayebi A, Samini M, Reyhani-Rad S, Babapour V. 5-ht(1a) receptor activation improves anti-cataleptic effects of levodopa in 6-hydroxydopamine-lesioned rats. Daru 2011;19(5):338-43.
29. Nayebi AM. Hypothesis: A promising effect of 5-HT1A receptor agonists in alleviating motor symptoms of Parkinson's disease. Afr J Pharm Pharmaco 2010; 4(6):289-290.
30. Heikkila R, Cohen G. Inhibition of biogenic amine uptake by hydrogen peroxide: A mechanism for toxic effects of 6-hydroxydopamine. Science 1971;172(3989):1257-8.
31. Mogi M, Togari A, Tanaka K, Ogawa N, Ichinose H, Nagatsu T. Increase in level of tumor necrosis factor (tnf)-alpha in 6-hydroxydopamine-lesioned striatum in rats without influence of systemic l-dopa on the tnf-alpha induction. Neurosci Lett 1999;268(2):101-4.
32. Glinka Y, Gassen M, Youdim MB. Mechanism of 6-hydroxydopamine neurotoxicity. J Neural Transm Suppl 1997;50:55-66.
33. Whitton PS. Inflammation as a causative factor in the aetiology of parkinson's disease. Br J Pharmacol 2007;150(8):963-76. doi: 10.1038/sj.bjp.0707167
34. Wang MJ, Lin WW, Chen HL, Chang YH, Ou HC, Kuo JS, et al. Silymarin protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity by inhibiting microglia activation. Eur J Neurosci 2002;16(11):2103-12.
35. Baluchnejadmojarad T, Roghani M, Mafakheri M. Neuroprotective effect of silymarin in 6-hydroxydopamine hemi-parkinsonian rat: Involvement of estrogen receptors and oxidative stress. Neurosci Lett 2010;480(3):206-10. doi: 10.1016/j.neulet.2010.06.038
36. Whishaw IQ, Whishaw P, Gorny B. The structure of skilled forelimb reaching in the rat: A movement rating scale. J Vis Exp 2008(18). doi: 10.3791/816
37. Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong JS, et al. Systemic lps causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007;55(5):453-62. doi: 10.1002/glia.20467
38. Sawada M, Imamura K, Nagatsu T. Role of cytokines in inflammatory process in parkinson's disease. J Neural Transm Suppl 2006(70):373-81.